Ticlid

(ticlopidine)

ApprovedSmall molecule

Roche

Ticlid is one of 102 small molecule programs targeting Stroke. It is currently in Approved.

Indications

Total Trials

Active Trials

101

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

Myocardial InfarctionActive, not recruiting

Peripheral Arterial DiseaseActive, not recruiting

StrokeApproved

Active, not recruiting

Myocardial InfarctionPhase 3

Active, not recruiting

Peripheral Arterial DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

Ticlid

Roche

Approved

1 2

Activase

Roche

Preclinical

19 3

Savella

AbbVie

Preclinical

1 4

Proamatine

Repatha

Pradaxa

3 7

Botox

RRevance Therapeutics, Inc.

Preclinical

2 8

Direct Anticoagulant

Bayer

Preclinical

3 9

Anticoagulants

Sanofi

Preclinical

1 10

Anticoagulant

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Peripheral Arterial Disease1 trial

Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease

Completed· Sanofi logo

Sanofi·Phase 3·NCT00862420·431 enrolled

Tramadol1 trial

Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol

Completed·TTurku University Hospital·Phase 4·NCT01214941·12 enrolled

Myocardial Infarction1 trial

Safety Evaluation of Clopidogrel Sulfate in Patients With Stable Angina/Old Myocardial Infarction to Whom Percutaneous Coronary Intervention is Being Planned

Completed· Sanofi logo

Sanofi·Phase 3·NCT00821834·1,003 enrolled

Esketamine1 trial

A Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT03298906·16 enrolled

Stroke1 trial

Antiplatelet Therapy to Prevent Stroke in African Americans

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 4·NCT00004727

Regulatory

FDA Approval Timeline[4]

Mar 24, 1993

TICLID

NDA NDA019979

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for ticlopidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ticlopidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ticlopidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA019979). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Roche

Ticlid

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Peripheral Arterial Disease1 trial

Tramadol1 trial

Myocardial Infarction1 trial

Esketamine1 trial

Stroke1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News